Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease

References

• Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22–8.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323–33.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 1997;337:1029–35.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402–13.
   PubMed Web of Science ®Google Scholar
• Isaacs KL. How rapidly should remission be achieved? Dig Dis 2010;28:548–55.
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463–8.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Kärkkäinen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008;28:1221–9.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40–6.
   PubMed Web of Science ®Google Scholar
• Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. the groupe d'etudes therapeutiques des affections inflammatoires digestives. Gut 1994;35:231–5.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002;97:2357–63.
   PubMed Web of Science ®Google Scholar
• Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003;17:1451–7.
   PubMed Web of Science ®Google Scholar
• Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002;123:707–13.
   PubMed Web of Science ®Google Scholar
• Rubin D, Reinisch W, Bensimon A, Yu A, Wu E, Mulani P, Predictors of clinical response and maintenance of response in Crohn's disease: data from CHARM. Am J Gastroenterol 2009;104:S478.
   Google Scholar
• Su C, Lichtenstein GR. Are there predictors of remicade treatment success or failure? Adv Drug Deliv Rev 2005;57:237–45.
   Google Scholar
• Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011;34:911–22.
   PubMed Web of Science ®Google Scholar
• Froslie KF, Jahnsen J, Moum BA, Vatn MH, IBSEN G. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–22.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295–301.
   PubMed Web of Science ®Google Scholar
• af Björkesten CG, Nieminen U, Turunen U, Arkkila PE, Sipponen T, Färkkilä MA. Endoscopic monitoring of infliximab therapy in Crohn's disease. Inflamm Bowel Dis 2011;17:947–53.
   Google Scholar
• Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'etudes therapeutiques des affections inflammatoires du tube digestif (GETAID). Gut 1989;30:983–9.
   PubMed Web of Science ®Google Scholar
• Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505–12.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010;16:2131–6.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D'Haens GR, Van Assche G, Sandborn WJ, Wolf DC, Colombel JF, Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease—first results of the EXTEND trial. Gastroenterology 2009;136:A116.
   Google Scholar
• Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis 2012;6:S224–34.
   Google Scholar
• Travis S, Feagan BG, Rutgeerts P, van Deventer S. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. J Crohns Colitis 2012;6:S250–9.
   Google Scholar
• Colombel JF, Sandborn WJ, Louis E, Panaccione R, Yang M, Chao J, Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: results from EXTEND. Abstract PO70, 6th congress of the European Crohn's and Colitis Organisation, Dublin, Ireland, February 24–26, 2011.
   Google Scholar
• Moskovitz DN, Daperno M, Van Assche G, Baert F, Gevers A, Sostegni R, Defining and validating cut-offs for the simple endoscopic score for Crohn's disease. Gastroenterology 2007;132:A-S1097.
   Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. national cooperative Crohn's disease study. Gastroenterology 1976;70:439–44.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979;77:843–6.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512–30.
   PubMed Web of Science ®Google Scholar
• von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803–13.
   PubMed Web of Science ®Google Scholar
• af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 2012;47:528–37.
   PubMed Web of Science ®Google Scholar
• D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218–24.
   PubMed Web of Science ®Google Scholar
• Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis 2012;18:2011–17.
   PubMed Web of Science ®Google Scholar